#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Heavy menstrual bleeding Hereditary haemorrhagic telangiectasia Meningitis meningococcal Ocular myasthenia Alexander disease Chondrosarcoma metastatic Cardiac arrest Nephropathy Salivary gland cancer Hereditary optic atrophy Acute hepatic failure Oesophageal atresia Cutaneous T-cell lymphoma stage II Spinal cord injury cervical Lung adenocarcinoma More trials…

    Learn about Rare Diseases

    Leiomyosarcoma recurrent Lymphatic malformation – Treatment Leukoencephalopathy – Trials in Disease Chordoma – Diagnostics Congenital hypotransferrinaemia Primary mediastinal large B-cell lymphoma – Trials in Disease Hyperoxaluria Crigler-Najjar syndrome Primary mediastinal large B-cell lymphoma – Diagnostics Systemic sclerosis pulmonary – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    CANNABINOL ETX-19477 Pariglasgene Brecaparvovec Melatonin PICLIDENOSON Jk06 Migalastat Teverelix Budesonide Alfacalcidol Protrans Alemtuzumab GXV813 Lanifibranor Exemestane Midazolam Doconexent IDOR-1117-2520C Human Vaccinia Immunoglobulin Gsk3915393 More therapies…

    Learn about Your Condition

    Hypogonadism male Metastases to lymph nodes Hepatic cancer Gender dysphoria Intervertebral disc protrusion Atrial fibrillation Ear discomfort Tympanic membrane perforation Primary hyperoxaluria Alcohol use disorder Small cell lung cancer Proteinuria Prodromal Alzheimer's disease Endocarditis bacterial Rhabdoid tumour More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Human epidermal growth factor receptor negative

  • A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Human epidermal growth factor receptor negative
    • Breast cancer
    Investigated Drugs:
    • Giredestrant
    • Abemaciclib
    France Germany Italy Spain

  • Study of Simvastatin with Nivolumab and Oxaliplatin for Patients with Advanced Stomach or Esophageal Cancer with ARID1A Mutation

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastrooesophageal cancer
    • Human epidermal growth factor receptor negative
    Investigated Drugs:
    • Simvastatin
    • Capecitabine
    • Fluorouracil
    Italy

  • Study of Patritumab Deruxtecan and Pembrolizumab for Patients with High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    • Hormone receptor positive HER2 negative breast cancer
    • Human epidermal growth factor receptor negative
    Investigated Drugs:
    • Patritumab Deruxtecan
    • Epirubicin Hydrochloride
    • Capecitabine
    Spain

  • Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer male
    • Human epidermal growth factor receptor negative
    • Breast cancer
    Investigated Drugs:
    • Elacestrant
    • Ribociclib
    Austria Germany Spain

  • Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Breast cancer female
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Ribociclib
    Germany

  • Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Giredestrant
    • Abemaciclib
    • Leuprorelin
    Austria Belgium Finland France Germany Greece +7
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!